Literature DB >> 16554488

Mutagenic potential of temozolomide in bone marrow cells in vivo.

Hartmut Geiger, David Schleimer, Kalpana J Nattamai, Stefanie R Dannenmann, Stella M Davies, Brian D Weiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16554488     DOI： 10.1182/blood-2005-09-3649

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.

Authors:  Michael D Milsom; Moran Jerabek-Willemsen; Chad E Harris; Axel Schambach; Emily Broun; Jeff Bailey; Michael Jansen; David Schleimer; Kalpana Nattamai; Jamie Wilhelm; Amanda Watson; Hartmut Geiger; Geoffrey P Margison; Thomas Moritz; Christopher Baum; Jürgen Thomale; David A Williams
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 2.  Aging of hematopoietic stem cells: DNA damage and mutations?

Authors:  Bettina M Moehrle; Hartmut Geiger
Journal:  Exp Hematol       Date:  2016-07-08       Impact factor: 3.084

3.  Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

Authors:  Pengfei Liu; Peiwen Li; Ting Lei; Limei Qu; Haiyan Huang; Qingchun Mu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

4.  Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs.

Authors:  Bettina M Moehrle; Kalpana Nattamai; Andreas Brown; Maria C Florian; Marnie Ryan; Mona Vogel; Corinna Bliederhaeuser; Karin Soller; Daniel R Prows; Amir Abdollahi; David Schleimer; Dagmar Walter; Michael D Milsom; Peter Stambrook; Matthew Porteus; Hartmut Geiger
Journal:  Cell Rep       Date:  2015-12-10       Impact factor: 9.423

Review 5.  Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients.

Authors:  David R Santiago-Dieppa; Jeffrey Steinberg; David Gonda; Vincent J Cheung; Bob S Carter; Clark C Chen
Journal:  Expert Rev Mol Diagn       Date:  2014-09       Impact factor: 5.225

6.  Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Shih-Chieh Lin; Yi-Chun Chang-Chien; Ming-Hsiung Chen; Sanford Ping-Chuan Hsu; Yu-Shu Yen; Wan-You Guo; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2015-01-10       Impact factor: 4.130

7.  Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report.

Authors:  Asim Jamal Shaikh; Nehal Masood
Journal:  J Med Case Rep       Date:  2010-08-18

Review 8.  Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.

Authors:  Nico Lachmann; Sebastian Brennig; Ruhi Phaltane; Michael Flasshove; Dagmar Dilloo; Thomas Moritz
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

9.  p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death.

Authors:  Ondrej Krejci; Mark Wunderlich; Hartmut Geiger; Fu-Sheng Chou; David Schleimer; Michael Jansen; Paul R Andreassen; James C Mulloy
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

10.  Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.

Authors:  Xu Chen; Norisato Mitsutake; Krista LaPerle; Nagako Akeno; Pat Zanzonico; Valerie A Longo; Shin Mitsutake; Edna T Kimura; Hartmut Geiger; Eugenio Santos; Hans G Wendel; Aime Franco; Jeffrey A Knauf; James A Fagin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.